Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Its proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. Genocea is conducting a Phase 1/2a clinical trial for GEN-011, an adoptive T cell therapy comprised of neoantigen-targeted peripheral cells. Also, Genocea continues to monitor patients in its Phase 1/2a GEN-009 neoantigen vaccine clinical trial. In addition to the two clinical programs, Genocea is conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $65M
Founded date: 2006
Investors 9
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.10.2012 | Series C | $30M | - |
| 03.01.2011 | Series B | $35M | - |
Mentions in press and media 28
| Date | Title | Description |
| 28.10.2021 | GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T - Form 8-K | GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., October 28, 2021 - Genocea Biosciences, Inc. (Nasdaq: G... |
| 29.07.2021 | Genocea Biosciences : Provides Second Quarter 2021 Corporate Update | GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NE... |
| 29.04.2021 | GENOCEA BIOSCIENCES, INC. GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T | GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., APRIL 29, 2021 - Genocea Biosciences, Inc. (NASDAQ: GNCA... |
| 29.04.2021 | GENOCEA BIOSCIENCES, INC. Genocea Biosciences : Provides First Quarter 2021 Corporate Update | GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, ... |
| 30.07.2020 | Bristol Myers Squibb and bluebird bio return to FDA; Takeda gets a breakthrough nod | More than two months after the FDA slammed Bristol Myers Squibb and bluebird bio with a suprise refuse-to-file on their “ide-cell” CAR-T therapy, the pair of developers have resubmitted their application. The new applicati... |
| 14.12.2018 | Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey exits Argos for Novadip; Frank Czerwiec is the new CMO at Goldfinch | → Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Therapeutics as president and CEO for the past eight years. Having led Novadip’s autologous cell therapy through a Phase I/IIa tria... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 12.02.2015 | Will the $350M fund Lux Capital is raising include digital health and biotech investments? | HIPAA compliance Aptible automates HIPAA compliance for Web-based and mobile applications. It manages servers, security, backups, encryption, and organizational permissions and helps them demonstrate proof of compliance. Big data Kyruus use... |
| 24.12.2014 | Our 5 most popular biotech and pharma stories of 2014 | This story was actually the most viewed story of the year. “After decades of stagnancy in the herpes therapeutics space, a real neck-and-neck race is emerging among three biotechs in the immunotherapy space: Genocea and Agenus, both based i... |
| 15.10.2014 | Herpes vaccine maker Genocea reports positive results a year after the first dose | “They had gone with what works: Taken what they thought were targets that B cells would recognize, and injected them as vaccines into people with HSV-2,” Clark said. “But they’ve shown nothing. While they’ve shown they can get an antibody r... |
Show more